Yale University

Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.

TitleEffect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.
Publication TypeJournal Article
Year of Publication2014
AuthorsSierra-Madero, Juan G., Susan S. Ellenberg, Mohammed S. Rassool, Ann Tierney, Pablo F. Belaunzarán-Zamudio, Alondra López-Martínez, Alicia Piñeirúa-Menéndez, Luis J. Montaner, Livio Azzoni, César Rivera Benítez, Irini Sereti, Jaime Andrade-Villanueva, Juan L. Mosqueda-Gómez, Benigno Rodriguez, Ian Sanne, and Michael M. Lederman
Corporate AuthorsCADIRIS study team
JournalThe lancet. HIV
Volume1
Issue2
Paginatione60-7
Date Published2014 Nov
ISSN2352-3018
AbstractImmune reconstitution inflammatory syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in patients with HIV. IRIS is associated with an increased risk of admission to hospital and death. We assessed whether CCR5 blockade with maraviroc reduces the risk of IRIS.
DOI10.1016/S2352-3018(14)70027-X
Alternate JournalLancet HIV

External Links